163 related articles for article (PubMed ID: 23689069)
1. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.
Hombach M; Somoskövi A; Hömke R; Ritter C; Böttger EC
Int J Med Microbiol; 2013 Jul; 303(5):270-6. PubMed ID: 23689069
[TBL] [Abstract][Full Text] [Related]
2. Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST.
Lucke K; Hombach M; Friedel U; Ritter C; Böttger EC
J Antimicrob Chemother; 2012 Jan; 67(1):154-8. PubMed ID: 21965431
[TBL] [Abstract][Full Text] [Related]
3. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
4. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex.
Maurer FP; Pohle P; Kernbach M; Sievert D; Hillemann D; Rupp J; Hombach M; Kranzer K
Clin Microbiol Infect; 2019 Mar; 25(3):379.e1-379.e7. PubMed ID: 29906595
[TBL] [Abstract][Full Text] [Related]
5. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
Fröberg G; Maurer FP; Chryssanthou E; Fernström L; Benmansour H; Boarbi S; Mengshoel AT; Keller PM; Viveiros M; Machado D; Fitzgibbon MM; Mok S; Werngren J; Cirillo DM; Alcaide F; Hyyryläinen HL; Aubry A; Andres S; Nadarajan D; Svensson E; Turnidge J; Giske CG; Kahlmeter G; Cambau E; van Ingen J; Schön T;
Clin Microbiol Infect; 2023 Jun; 29(6):758-764. PubMed ID: 36813087
[TBL] [Abstract][Full Text] [Related]
6. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
7. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China.
Zhang Z; Pang Y; Wang Y; Cohen C; Zhao Y; Liu C
Int J Antimicrob Agents; 2015 May; 45(5):491-5. PubMed ID: 25795316
[TBL] [Abstract][Full Text] [Related]
8. Drug susceptibility distributions of
Schulthess B; Schäfle D; Kälin N; Widmer T; Sander P
Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33619057
[TBL] [Abstract][Full Text] [Related]
9. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791
[TBL] [Abstract][Full Text] [Related]
10. Difference in drug susceptibility distribution and clinical characteristics between
Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
[No Abstract] [Full Text] [Related]
11. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
He G; Wu L; Zheng Q; Jiang X
Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
[No Abstract] [Full Text] [Related]
13. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
[TBL] [Abstract][Full Text] [Related]
14. Drug susceptibility testing of nontuberculous mycobacteria.
van Ingen J; Kuijper EJ
Future Microbiol; 2014; 9(9):1095-110. PubMed ID: 25340838
[TBL] [Abstract][Full Text] [Related]
15. [Non-tuberculous mycobacteriosis. What has been coming out].
Kajiki A
Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
[TBL] [Abstract][Full Text] [Related]
16. [Frequently Isolated Slow Growing Nontuberculous Mycobacteria from Pulmonary Samples and Evaluation of Drug Susceptibility Testing Results in a Referral Hospital in Turkey].
Ceyhan İ; Özkara Ş; Güler MZ; Dulkar G; Altınsoy R; Vezir S
Mikrobiyol Bul; 2019 Jul; 53(3):330-335. PubMed ID: 31414634
[TBL] [Abstract][Full Text] [Related]
17.
Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
[TBL] [Abstract][Full Text] [Related]
18. [Antimicrobial susceptibility and genotyping of
Wang SQ; Jiang GL; Wei GM; Huo FM; Dong LL; Zhao LP; Huang HR; Wang GR
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Jul; 41(7):539-543. PubMed ID: 29996350
[No Abstract] [Full Text] [Related]
19. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
Alcaide F; Calatayud L; Santín M; Martín R
Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]